|
1）日本消化器内視鏡学会卒後教育委員会．消化器内視鏡ガイドライン．日本消化器内視鏡学会，監修．東京: 医学書院; 1999
|
|
|
|
|
2）小越和栄，金子榮藏，多田正大，他．日本消化器内視鏡学会リスクマネージメント委員会: 内視鏡治療時の抗凝固薬，抗血小板薬使用に関する指針．日消内誌．2005; 47: 2691-5
|
|
|
|
|
|
3）日本消化器内視鏡学会卒後教育委員会．消化器内視鏡ガイドライン第3版．日本消化器内視鏡学会，監修．東京: 医学書院; 2006
|
|
|
|
|
|
4）藤本一眞，藤城光弘，加藤元嗣，他．抗血栓薬服用者に対する消化器内視鏡診療ガイドライン．Gastroenterol Endosc. 2012; 54: 2074-102
|
|
|
|
|
|
5）笹貫 宏，青崎正彦，池田康夫，他．循環器疾患における抗凝固・抗血小板療法に関するガイドライン．Circuation. 2004; 64: 1153-1219
|
|
|
|
|
|
6）Standards of Practice Committee of ASGE: Guideline on the management of anticoagulation and antiplatelet therapy for endoscopic procedure. Gastroinset Endosc. 2002; 55: 775-98
|
|
|
|
|
|
7）2008年合同研究班報告．循環器疾患における抗凝固・抗血小板療法に関するガイドライン（2009年改定版）．http://www.j-circ.or.jp/guideline/pdf/JCS2009_hori_d.pdf
|
|
|
|
|
|
8）脳卒中合同ガイドライン委員会．脳卒中治療ガイドライン2009，篠原幸人，他編集．東京: 協和企画; 2009
|
|
|
|
|
|
9）Sieg A, Hachmoeller-Eisenbach U, Eisenbach T. Prospective evaluation of complications in outpatients GI endoscopy: a survey among German gastroendoscopits. Gastrointest Endosc. 2000; 51: 37-41
|
|
|
|
|
10）Parra-Blanco A, Kaminaga N, Kojima T, et al. Hemoclipping for postpolypectomy and postbiopsy colonic bleeding. Gastrointest Endosc. 2000; 51: 37-41
|
|
|
|
|
|
11）Blacker DJ, Wijdicks EF, McClelland RL. Stroke risk in anticoagulated patients with atrial fibrillation undergoing endoscopy. Neurology. 2003; 61: 964-8
|
|
|
|
|
|
12）Wahl MJ. Dental surgery in anticoagulated patients. Arch Intern Med. 1998; 158: 1610-6
|
|
|
|
|
|
13）Palareti G, Legnani C, Guazzaloca G, et al. Activation of blood coagulation after abrupt or stepwise withdrawal of oral anticoagulants--a prospective study. Thromb Haemost. 1994; 72: 222-6
|
|
|
|
|
|
14）Sibon I, Orgogozo JM. Antiplatelet drug discontinuation is a risk factor for ischemic stroke. Neurology. 2004; 62: 1187-9
|
|
|
|
|
|
15）Maulaz AB, Bezerra DC, Michel P, et al. Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Arch Neurol. 2005; 62: 1217-20
|
|
|
|
|
|
16）Anderson MA, Ben-Menachem T, TGan SI, et al. Guideline: Management of antithrombotic agents for endoscopic procedures. Gastrointest Endosc. 2009; 70: 1060-70
|
|
|
|
|
|
17）Boustière C, Veitch A, Vanbiervliet G, et al. Endoscopy and antiplatelet agents. European Society of Gastrointestinal Endoscopy （ESGE） guideline. Endoscopy. 2011; 43: 445-58
|
|
|
|
|
|
18）Whitson MJ, Dikman AE, von Althann C, et al. Is gastroduodenal biopsy safe in patients receiving aspirin and clopidogrel? J Clin Gastroenterol. 2011; 45: 228-33
|
|
|
|
|
|
19）Shiffman ML, Farrel MT, Yee YS. Risk of bleeding after endoscopic biopsy or polypectomy in patients taking aspirin or other NSAIDS. Gastrointest Endosc. 1994; 40: 458-62
|
|
|
|
|
|
20）Ono S, Fujishiro M, Hirano K, et al. Retrospective analysis on the management of anticoagulants and antiplatelet agents for scheduled endoscopy. J Gastroenterol. 2009; 44: 1185-9
|
|
|
|
|
21）Ono S, Fujishiro M, Kanzaki H, et al. Conflicting clinical environment about the management of antithrombotic agents during the periendoscopic period in Japan. J Gastroenterol Hepatol. 2011; 26: 1434-40
|
|
|
|
|
|
22）Yousfi M, Gostout CJ, Baron TH, et al. Postpolypectomy lower gastrointestinal bleeding: potential role of aspirin. Am J Gastroenterol. 2004;99: 1785-9
|
|
|
|
|
|
23）Gerson LB, Triadafilopoulos G, Gage BF. The management of anticoagulants in the periendoscopic period for patients with atrial fibrillation: a decision analysis. Am J Gastroenterol. 2004; 116: 451-9
|
|
|
|
|
|
24）Choudari CP, Rajgopal C, Palmer KR. Acute gastrointestinal haemorrhage in anticoagulated patients: diagnoses and response to endoscopic treatment. Gut. 1994; 35: 464-6
|
|
|
|
|
|
25）Baron TH, Harewood GC. Endoscopic balloon dilation of the biliary sphincter compared to endoscopic biliary sphincterotomy for removal of common bile duct stones during ERCP: a metaanalysis of randomized, controlled trials. Am J Gastroenterol. 2004; 99: 1455-60
|
|
|
|
|
|
26）Hussain N, Alsulaiman R, Burtin P, et al. The safety of endoscopic sphincterotomy in patients receiving antiplatelet agents: a case-control study. Aliment Pharmacol Ther. 2007; 25: 579-84
|
|
|
|
|
|
27）Ono S, Fujishiro M, Niimi K, et al. Technical feasibility of endoscopic submucosal dissection for early gastric cancer in patients taking anti-coagulants or anti-platelet agents. Dig Liver Dis. 2009; 41: 725-8
|
|
|
|
|
|
28）Metz AJ, Bourke MJ, Moss A, et al. Factors that predict bleeding following endoscopic mucosal resection of large colonic lesions. Endoscopy. 2011; 43: 506-11
|
|
|
|
|
|
29）Singh M, Mehta N, Murthy UK, et al. Postpolypectomy bleeding in patients undergoing colonoscopy on uninterrupted clopidogrel therapy. Gastrointest Endosc. 2010; 71: 998-1005
|
|
|
|
|
|
30）間部克裕，平山眞章，加藤元嗣．内視鏡治療における抗凝固薬，抗血小板薬の休薬方法．日消内誌．2010; 52: 2976-84
|
|
|
|
|
|
31）White RH, McKittrick T, Hutchinson R, et al. Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. Ann Intern Med. 1995; 1: 40-2
|
|
|
|
|
|
32）Guerrouij M, Uppal CS, Alklabi A, et al. The clinical impact of bleeding during oral anticoagulant therapy : Assessment of morbidity, mortality and post-bleed anticoagulant management. J Thromb Thrombolysis. 2011; 31: 419-23
|
|
|
|
|
|
33）Hui AJ, Wong RM, Ching JY, et al. Risk of colonoscopic polypectomy bleeding with anticoagulants and antiplatelet agents: analysis of 1657 cases. Gastrointest Endosc. 2004; 59: 44-8
|
|
|
|
|
|
34）Garcia DA, Regan S, Henault LE, et al. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med. 2008; 14: 63-9
|
|
|
|
|
|
35）Yasaka M, Minematsu K, Yamaguchi T. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation．Intern Med. 2001; 40: 1183-8
|
|
|
|
|
36）Constans M, Santamaria A, Mateo J, et al. Low-molecular-weight heparin as bridging therapy during interruption of oral anticoagulation in patients undergoing colonoscopy or gastroscopy. Int J Clin Pract. 2007; 61: 212-7
|
|
|
|
|
|
37）Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361: 1139-51
|
|
|
|
|
|
38）Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy （RE-LY） Trial. Circulation. 2011; 123: 2363-72
|
|
|
|
|
|
39）Holster IL, Valkhoff VE, Kuipers EJ, et al. New oral anticoagulants increase risk for gastrointestinal bleeding: A systematic review and meta-analysis. Gastroenterology. 2013; 145:105-12
|
|
|
|
|
|
40）Harrison L, Johnston M, Massicotte MP, et al. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med. 1997; 15: 133-6
|
|
|
|
|
|
41）Stangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol. 2005; 45: 555-63
|
|
|
|
|